Patrick Campbell

The FDA approved updated labeling for lumateperone showing a 63% lower relapse risk in adults with schizophrenia in a phase 3 trial.

The FDA cleared Tandem's Control-IQ+ as the first AID system approved for pregnancy in type 1 diabetes, backed by the CIRCUIT trial.

Two-year CAHtalyst Adult data show crinecerfont enabled sustained glucocorticoid dose reductions while maintaining androgen control in classic CAH.

Otarmeni is the first FDA-approved gene therapy for OTOF-related hearing loss, showing rapid hearing gains in the CHORD trial.

Older adults with both anemia and elevated neurofilament light chain levels faced a more than 3.5-fold increased risk of developing dementia.

FDA clears once-daily icotrokinra pill for moderate-to-severe plaque psoriasis, with strong PASI responses and placebo-like safety.

A new monthly podcast digs into modern primary care, from policy and prevention to social determinants and patient trust, through candid talks with leaders.

Survey shows GI stigma makes Americans dismiss symptoms, delaying diagnosis and driving costs—why primary care conversations matter.

ACP pushes disability-inclusive training, streamlined accommodations, and accessible clinics to narrow health gaps for disabled patients.

Long-term stress links to higher postpartum blood pressure only after pregnancy complications, suggesting stress screening and management may help reduce future CVD risk.

Phase 3 FINE-ONE shows finerenone cuts protein in urine for type 1 diabetes CKD patients, with manageable safety, hinting at new kidney protection.